Association between C-reactive protein genotype, circulating levels, and aortic pulse wave velocity by Schumacher, Wiebke et al.
Ben-Shlomo
Gallacher, Ann Rumley, Gordon Lowe, George Davey Smith, Ian B. Wilkinson and Yoav 
Wiebke Schumacher, John Cockcroft, Nicholas J. Timpson, Carmel M. McEniery, John
Wave Velocity
Association Between C-Reactive Protein Genotype, Circulating Levels, and Aortic Pulse
Print ISSN: 0194-911X. Online ISSN: 1524-4563 
Copyright © 2008 American Heart Association, Inc. All rights reserved.
is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231Hypertension 
doi: 10.1161/HYPERTENSIONAHA.108.117622
2009;53:150-157; originally published online December 15, 2008;Hypertension. 
 http://hyper.ahajournals.org/content/53/2/150
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
  
 http://hyper.ahajournals.org//subscriptions/
is online at: Hypertension  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Permissions and Rights Question and Answer this process is available in the
click Request Permissions in the middle column of the Web page under Services. Further information about
Office. Once the online version of the published article for which permission is being requested is located, 
 can be obtained via RightsLink, a service of the Copyright Clearance Center, not the EditorialHypertensionin
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:
 at Cardiff University on February 19, 2014http://hyper.ahajournals.org/Downloaded from 
Association Between C-Reactive Protein Genotype,
Circulating Levels, and Aortic Pulse Wave Velocity
Wiebke Schumacher, John Cockcroft, Nicholas J. Timpson, Carmel M. McEniery, John Gallacher,
Ann Rumley, Gordon Lowe, George Davey Smith, Ian B. Wilkinson, Yoav Ben-Shlomo
Abstract—Circulating C-reactive protein (CRP) level is associated with cardiovascular disease. Whether this relationship
is causal has been subject of debate, especially as a potential therapeutic target. Previous studies have demonstrated an
association between circulating CRP levels and arterial pulse wave velocity, an accepted measure of arterial stiffness.
We investigated the association between circulating CRP levels, CRP genotype, and aortic pulse wave velocity by
examining data on 790 healthy male participants of the Caerphilly study. Circulating CRP levels were associated with
aortic pulse wave velocity after adjustment for cardiovascular risk factors and other potential confounders (P0.001).
Three single nucleotide polymorphisms in the CRP gene (rs1130864, rs1800947, and rs1205) were associated with
differences in circulating CRP levels (ratio of geometric means: 1.12, 95% CI 1.03 to 1.21, P0.005; 0.76, 95% CI 0.66
to 0.87, P0.001; 0.88, 95% CI 0.81 to 0.95, P0.001, respectively). However, there was no relationship between any
of the genotypes and aortic pulse wave velocity (regression coefficient for C:G/G:G versus C:C genotypes for single
nucleotide polymorphism rs1800947 0.005; 95% CI, 0.57 to 0.58; P0.99). These results suggest that although
circulating CRP levels are associated with aortic pulse wave velocity, CRP does not have a causal role in the
development of arterial stiffness. CRP may simply act as a marker of vascular damage (ie, reverse causality), or the
association reflects residual confounding. Further studies are needed to confirm these findings, particularly in view of
the central role CRP has played in cardiovascular disease so far. (Hypertension. 2009;53:150-157.)
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Atherosclerosis is increasingly thought of as an inflam-matory process1 in which the acute phase reactant
C-reactive protein (CRP) may be an important contributor.
Elevated CRP levels have been positively associated with
incident cardiovascular disease,2 and some studies suggest that
CRP could be used as a novel predictor in risk assessment.
However, compared with classical risk factors for ischemic
heart disease, CRP does not add greatly to current risk
prediction models.3,4 Thus, it remains unclear whether CRP is
solely a surrogate marker of cardiovascular disease5 or
causally related to it. In particular, a causal relation would
raise the question of whether high-risk persons should have
interventions to lower their CRP levels2 and whether CRP
antagonists merit evaluation in acute ischemia.6 Two stud-
ies7,8 even report that statin therapy reduces circulating CRP
levels and thereby causes a reduction in atherosclerotic
disease progression and improved cardiovascular outcomes.
Under the assumption of a CRP effect being causal, one
potential mechanism linking inflammation and CRP to car-
diovascular disease is arterial stiffening. The gold standard
measure of stiffness is aortic pulse wave velocity (aPWV),
which can be measured noninvasively and has been shown to
be associated with the presence of atherosclerotic plaques.9
Numerous studies report an association between CRP and
PWV,10–21 but, in some, the association disappears or be-
comes borderline after adjustment for classical cardiovascular
disease risk factors, such as cholesterol, smoking, and fea-
tures of the metabolic syndrome.11,12,22 Several studies have
reported no association between CRP and PWV.23,24
Observational studies experience residual problems of
poorly measured or unmeasured confounding and reverse
causality when the disease process has an incipient onset and
long latency period. One approach to overcome these prob-
lems is the use of Mendelian randomization, whereby func-
tional genotypic variants serve as markers of exposure unre-
lated to other covariates and, hence, overcome issues with
confounding and reverse causality.25 Hence, if elevated cir-
culating CRP is causally related to increased stiffness, one
would expect a higher aPWV in those persons with genotypes
that generate higher circulating CRP.
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To our knowledge, 2 cross-sectional studies have examined
the relationship between CRP gene polymorphisms (single
nucleotide polymorphisms [SNPs]) with circulating CRP
levels and aPWV. Morita et al26 describe in their study an
association between CRP genotype and aPWV among a
sample of 315 elderly Japanese men and women. However, a
recent community-based cross-sectional study by Schnabel et
al27 of participants of the Framingham Heart Study (n2409)
has not found such an association.
Therefore, the aim of this study was to confirm observa-
tional relationships between circulating CRP and PWV and
then compare these to the association between polymor-
phisms in the CRP gene known to be associated with
circulating CRP and PWV in a prospective cohort. These data
Table 1. Baseline Characteristics of Participants
Participants With aPWV Reading Participants Without aPWV Reading
Subject Characteristics n Mean or Percentage SD/IQR n Mean or Percentage SD/IQR
Age, y 790 55.5 4.2 1608 57.6‡ 4.5
BMI, kg/m2 782 26.4 3.2 1580 26.5* 3.8
Waist–hip ratio 763 0.9 0.1 1228 0.9‡ 0.07
SBP, mm Hg 784 142.7 21.8 1582 148.1‡ 22.9
DBP, mm Hg 784 84.2 11.3 1582 85.1* 12.6
aPWV, m/s 790 11.5 2.8
CRP,§ mg/L 662 1.4 0.8, 2.5 1304 2.0‡ 1.1, 3.9
Triglycerides,† mmol/L 770 1.7 1.2, 2.2 1532 1.7† 1.2, 2.4
Total cholesterol, mmol/L 770 5.7 1.0 1532 5.6* 1.0
HDL cholesterol, mmol/L 770 1.1 0.3 1532 1.0‡ 0.25
Liver function tests
-Glutamyltransferase,§ IU/L 762 24.7 17, 35 1507 27.1‡ 18, 38
Total alkaline phosphatase,§ U/L 758 157.8 128, 200 1494 175.2‡ 139, 220
Liver alkaline phosphatase,§ U/L 755 86.9 68, 107 1487 98.4‡ 74, 129
Alcohol consumption,§ U/wk 749 7.7 2.3, 21.3 1478 7.0* 1.4, 18.2
Smoking status, % 787
Nonsmokers 196 24.9% 235 14.6%
Ex-smokers 341 43.3% 566 35.3%
Cigar, pipe, or 15 cigarettes/day 151 19.2% 455 28.4%
15 cigarettes/day 99 12.6% 349 21.7%
Diabetic status 790
No 775 98.1% 1532 95.3%
Yes/uncertain 15 1.9% 75 4.7%
Activity scores 789 790
Leisure
Mild 220 27.9 575 36.1
Moderate 299 37.9 496 31.1
Heavy 270 34.2 524 32.9
Work
Mild 262 33.2 557 33.4
Moderate 371 47 747 44.8
Heavy 157 19.9 362 21.7
Social class 789
Manual 471 59.7 1139 71.1
Nonmanual 318 40.3 462 28.9
Presence of IHD 790
No 603 76.3 1059 65.9
Probable/yes 187 23.7 549 34.1
IQR indicates interquartile range; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; IHD, ischemic heart disease.
P values indicate significance of difference between participants in each group; *P0.05; †P between 0.01 to 0.05; ‡P0.001.
§Geometric mean.
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allow us to comment on whether the existing association
between circulating CRP and PWV is likely to be causal or
explained by residual confounding, reverse causality, or both.
Methods
Subjects
The Caerphilly Prospective Study is a population-based male cohort
study of all men 45 to 59 years of age who were resident in the small
South Wales town of Caerphilly. The initial examination (phase 1)
took place between 1979 and 1983. Of the 2818 eligible men, 2512
(89%) were recruited. An additional 447 patients were recruited at
phase 2 so that some men have no phase 1 data. Men were reinvited
for additional follow-up approximately every 5 years. The last
follow-up (phase 5) occurred between 2002 and 2004.
Subjects gave written informed consent, and the study had the
approval of the local research ethics committee. At commencement,
a detailed questionnaire with a review of personal and medical
history was collected. Items included occupational social class
(grouped as an ordinal variable: I, II, IIINM; IIIM; IV, V), work and
leisure time activity, vasoactive medication use, alcohol intake, and
smoking habit.
Clinic Measures at Phase 2
Height in bare feet was measured using a Holtain stadiometer and
weight in light clothes using standardized scales, from which we
derived body mass index. Peripheral blood pressure was measured in
duplicate using a Hawksley random zero sphygmomanometer at
phases 1 and 2. Waist and hip circumference were measured by
standard methods and expressed as waist–hip ratio.
Venous Blood Samples
At phases 1 and 2, subjects attended an early morning clinic, and a
fasting blood sample was taken with minimal venous stasis. This was
assayed for CRP, triglycerides, liver function tests (liver and total
alkaline phosphatase, -glutamyltransferase), insulin, and glucose.
In phase 1, CRP was measured using an in-house ELISA method
(details have been described previously5). In phase 2, CRP was
measured in a citrated sample, which had been centrifuged within 1
hour and stored at 70°C and analyzed using a high-sensitivity
nephelometric assay (Dade-Behring). A direct comparison of the 2
assays has not been performed.
aPWV at Phase 5
aPWV was measured in duplicate in the supine position after 10
minutes of rest. aPWV was measured by sequentially recording
ECG-gated carotid and femoral artery waveforms. Wave transit time
was calculated by the system software, using the R wave of a
simultaneously recorded ECG as a reference frame (Sphygmocor;
AtCor Medical, Sydney, Australia). The distance from the sternal
notch to femoral and carotid probe recording sites was obtained with
a tape measure. aPWV was determined by dividing the distance
between the 2 recording sites by the wave transit time. Mean arterial
pressure in phase 5 was derived from duplicate peripheral blood
pressure measurements using an Omron 711 automatic.
Genotyping
Genetic variants of the CRP gene on chromosome 1q21-q23 were
identified on blood samples taken at phase 4. Three SNPs were used
in the analysis; rs1130864 (G-A base change in the 3 untranslated
region, AF449713 position 3014), rs1800947 (C-G base change at
codon 188, AF449713 position 2667), and rs1205 (C-T base change
in the 3 flanking/untranslated region, AF449713 position 3872).
These SNPs were chosen on the basis of available evidence showing
their replicable and robust association with circulating CRP levels.28–30
Genotyping was undertaken by Kbiosciences (Hertfordshire, UK),
which designed and used assays based on its proprietary competitive
allele-specific polymerase chain reaction system method (www.
kbioscience.co.uk). All assays were validated before use with a
standard 96-well validation plate used by Kbiosciences. All variants
were checked for adherence to Hardy–Weinberg equilibrium to
avoid gross genotyping error, and a small number of internal
validations and non-DNA test controls were used to validate geno-
typing after assay. Hardy–Weinberg equilibrium was tested at each
SNP locus on a contingency table of observed-versus-predicted
genotypic frequencies using an exact test. Our allelic frequencies at
rs1800947 represent the base on the antisense strand, and C and G
frequencies are therefore reversed in our analyses. The G allele is the
predominant allele in worldwide SNP frequency studies (www.
ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs1800947); this equates to our
C allele on the antisense strand.
Statistics
Statistical analysis was conducted in Stata version 10. The average
aPWV value was derived from 2 measures unless only 1 was
available. We log-transformed variables that were positively skewed
(eg, CRP, triglycerides, and alkaline phosphatases). After transfor-
mation of CRP, we standardized the values and expressed them as z
scores because the assays were done in different laboratories. We
then took the average value for the z scores for phases 1 and 2, unless
there was only 1 value, in which case we took this instead. This
removes problems associated with the different laboratory assays
Table 2. Association Between CRP Genotypes and Circulating CRP Levels (mg/L)
Genotype (n) SNP Mean CRP (mg/L) Geometric Mean CRP GM/Ratio* 95% CI P Value
rs1130864
G:G (532) 2.48 1.49
G:A (496) 2.67 1.69 1.13 1.01, 1.27 0.03
A:A (135) 3.02 1.85 1.24 1.04, 1.47 0.02
Per allele 1.12 1.03, 1.21 0.005
rs1800947
C:C (998) 2.76 1.69
C:G/G:G† (166) 1.96 1.28 0.76 0.66, 0.87 0.001
rs1205
C:C (538) 2.80 1.77
C:T (490) 2.60 1.54 0.87 0.78, 0.98 0.02
T:T (134) 2.11 1.37 0.78 0.66, 0.92 0.004
Per allele 0.88 0.81, 0.95 0.001
*GM/ratio is the relative difference in geometric means between genotypes and per allele.
†Combined heterozygote and minor homozygote allele because of small numbers.
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because it essentially rescales the raw data along comparable ranges.
Where CRP was the outcome variable, we simply used the log–CRP
values because then the back-transformed regression coefficients
represent the ratio of geometric means in CRP (eg, 1.20 implies a
20% relative increase in geometric mean value of CRP for a unit
change in exposure status). In all analyses, PWV was adjusted for
current age, heart rate, mean arterial pressure, and vasoactive
medication use (measured at phase 5) because these are all strong
predictors of PWV.
We calculated the strength of the association between CRP and
aPWV by using linear regression. Multivariable regression was used
to examine whether simple associations were changed after adjust-
ment for potential confounders or intermediaries. We considered the
following as potential confounders as a measure of socioeconomic
status: body mass index, waist–hip ratio, triglycerides, high-density
lipoprotein (HDL) and total cholesterol, systolic blood pressure, liver
function tests (which may influence CRP synthesis), smoking status
(never, ex-smoker, or current smoker), physical activity, diabetic
status, prevalent ischemic heart disease, and social class (manual
versus nonmanual).
Haplotypes were constructed using the genetic data analysis program
SIMHAP (http://www.genepi.com.au). SIMHAP uses current
estimation–maximization-based methods for the estimation of haplo-
types from unphased genotype data.31 The current implementation of
SIMHAP uses the statistical computing package R (www.r-project.org)
to resolve haplotypes and provide their posterior probabilities.
After the construction of haplotypes, SIMHAP is also able to
examine relationships between common CRP haplotypes and circu-
lating CRP concentration. All possible haplotype configurations are
resolved for each individual within the program itself, and the
posterior probability of each configuration is calculated. Association
analyses within the generalized linear model framework then uses
simulation to correctly deal with the uncertainty around imputed
haplotypes. In the case of plasma CRP concentration, mean values by
common CRP haplotype were derived from the regression coeffi-
cients and CIs estimated by SIMHAP. For these analyses, all
common haplotypes were run in the model assuming additive effect
of each haplotype and setting a baseline haplotype as the most
common in this sample (1000 iterations were used). This was then
repeated with log-transformed aPWV for ease of comparison.
Results
Of the 2398 members from phase 2, 906 men (37.8%) died
before we could undertake measurement of their aPWV. A
total of 103 men were known to have moved out of the area,
Table 3. Mean Values and Coefficients for Each Genotype of SNP rs1800947
Subject Characteristics C:C C:G/G:G
Difference
(-coefficient or %) 95% CI P Value
Age, y 56.8 56.5 0.29 0.96, 0.38 0.40
BMI, kg/m2 26.6 26.5 0.11 0.67, 0.44 0.69
Waist–hip ratio 0.93 0.93 0.0001 0.01, 0.01 0.98
SBP, mm Hg 145.5 146.5 0.98 2.45, 4.41 0.57
DBP, mm Hg 84.4 84.3 0.07 1.84, 1.70 0.93
Triglycerides,* mmol/L 1.69 1.65 0.98† 0.9, 1.06 0.59
Total cholesterol, mmol/L 5.62 5.48 0.15 0.3,0.003 0.05
HDL cholesterol, mmol/L 1.03 1.02 0.004 0.04, 0.03 0.81
Liver function tests
-Glutamyltransferase,* IU/L 25.53 24.85 0.97† 0.89, 1.06 0.55
Total alkaline phosphatase,* U/L 165.6 164.37 0.99† 0.95, 1.04 0.75
Liver alkaline phosphatase,* U/L 91.46 88.93 0.97† 0.92, 1.03 0.36
Alcohol consumption,* U/week 7.43 7.34 0.99† 0.77, 1.26 0.92
Smoking status, %
Nonsmokers 18.3 24.1
Ex-smokers 40.1 34.4
Cigar, pipe or 15 cigarettes/day 25.1 25.1 0.22‡
15 cigarettes/day 16.6 16.4 0.2 5.9, 5.4 0.94
Diabetic status, %
No 96.7 98.0
Yes/uncertain 3.3 2.1 1.2 3.8,1.4 0.37
Activity scores, %
Leisure 31.7 26.2
Mild
Moderate 33.8 34.4 0.26‡
Heavy 34.7 39.5 4.8 2.4, 12.1 0.19
Work
Mild 32.0 39.1
Moderate 47.0 41.1 0.13‡
Heavy 21.1 19.8 1.3 7.4, 4.8 0.68
*Geometric mean; †geometric mean ratio between 2 alleles; ‡P value for heterogeneity.
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so they were not invited, leaving 1389 potential men. A total
of 124 men could not be found at their last known addresses,
and 438 men either refused to take part or felt unable to attend
the clinic, resulting in 827 phase 2 men, of whom 790 had
valid measures of aPWV (62.5% of men contacted).
Table 1 shows the baseline characteristics of participants
with aPWV and subjects who were lost to follow-up. Subjects
who were in the initial phases but who had no aPWV at phase
5 were more likely to have higher values for waist–hip ratio,
systolic blood pressure, and levels of circulating CRP, tri-
glycerides, HDL cholesterol, -glutamyltransferase, total and
liver alkaline phosphatase (P0.05). This is consistent with
the healthy survivor effect: participants who had died by
phase 5 (ie, the majority of the group without aPWV reading)
were more likely to have had more advanced cardiovascular
damage, reflected by higher systolic blood pressure and
circulating levels of cholesterol and CRP. When we com-
pared CRP genotypes of men in phase 5 with the group
without aPWV reading, we noted that although there was a
3% difference in allele distribution, the P value was 0.1;
hence, this finding is consistent with chance.
The genotypes of the 3 SNPs were in Hardy–Weinberg
equilibrium (rs1130864 P0.08; rs1800947 P0.99; rs1205
P0.1). Because of low numbers in the minor homozygote
for SNP rs1800947 (G:G n8), we combined this group with
the heterozygote as C:G/G:G (n166).
We looked at the association between CRP genotypes and
circulating levels of CRP, and for all 3 SNPs, there was a
significant allelic difference in CRP levels for each genotype
(rs1130864 P0.005; rs1800947 P0.001; rs1205 P0.001;
Table 2). The difference was greatest for rs1800947, with a
ratio of geometric means of 0.76.
We then checked the Mendelian randomization assumption
that our CRP genotype would be unrelated to other potential
confounders (Table 3). Only total cholesterol levels showed
nominal difference by genotype (0.15; P0.05), but
given that there are 18 tests of statistical significance, this
would not survive correction for multiple testing (P0.9
after Bonferroni correction).
Table 4 shows the results for regression analyses relat-
ing circulating CRP to aPWV (models 1 through 4) and for
CRP genotype (rs1800947) to aPWV (models 5 and 6). For
the sake of simplicity, we only presented this genotype in
the table because of all SNPs, it explained the greatest
proportion of variance in circulating CRP (ratio of geo-
metric means comparing C:C to C:G/G:G 0.77; P0.001).
In model 1, the linear regression analysis between circu-
lating CRP (log-transformed) and aPWV shows an associ-
ation with a -coefficient of 0.46 (P0.001) for a 1
log-unit change in CRP levels. In models 2 through 4, we
added various potential confounders in a sequential order,
such that model 2 includes diabetes mellitus, body mass
index, systolic blood pressure, waist– hip ratio, smoking
status, and social class. Model 3 additionally includes
triglycerides, cholesterol, high-density cholesterol,
-glutamyltransferase, liver and total alkaline phosphatase,
and alcohol consumption, and in model 4, we added
presence of ischemic heart disease and work/leisure activ-
ity. Some variables were not measured on the whole
cohort; hence, the total number of subjects incorporated in
the multivariable regression models decreased to 549.
Despite this attenuation of numbers, results show only a
modest reduction of effect (0.39 after adjustment for a
range of confounders) with strong evidence against the
null hypothesis (P0.001).
Model 5 shows that there is no difference in aPWV between
the C:C and C:G/G:G genotypes (0.005, 95% CI, 0.57 to
0.58, P0.99). This remained essentially unchanged when
cholesterol levels were added in model 6 (0.03, 95% CI,
0.56 to 0.62, P0.93). The results for aPWV with the other 2
genotypes were as follows; for rs1130864 0.003, 95% CI,
0.28 to 0.28, P0.98; for rs1205 0.104, 95% CI,0.39
to 0.18, P0.47.
We repeated the analysis with common (5%) constructed
haplotypes and found largely the same patterns of association.
Table 5 shows common haplotypes, their frequency and their
relationship with both circulating CRP and aPWV. Specifi-
cally, haplotype 212/GGT for the SNPs rs1800947,
rs1130864 and rs1205 (taken as that which was observed to
have the greatest effect on circulating CRP) was associated
with a reduction in circulating CRP when compared with the
ancestral haplotype 111 (geometric mean for circulating CRP
for haplotype 1111.75 (1.55, 2.00), ratio of geometric
means for haplotype 2120.79 (0.67, 0.93), P0.004. For
the same haplotype, there was no observed association with
aPWV (geometric mean for the baseline haplotype
11111.16 (10.75, 11.58), ratio of geometric means for
haplotype 2121.01 (0.96, 1.07), P0.7).
Discussion
Our results confirm the established association between
circulating CRP and aPWV, and show a robust association
Table 4. Association Among CRP Genotype, Circulating CRP,
and aPWV*
CRP Serum/
Genotype n (Frequency) -Coefficient 95% CI P Value
Circulating
CRP
Model 1 646 0.46 0.26, 0.67 0.001
Model 2 608 0.39 0.18, 0.61 0.001
Model 3 551 0.40 0.17, 0.63 0.001
Model 4 549 0.39 0.15, 0.62 0.001
SNP
rs1800947
C:G/G:G vs C:C
Model 5 565 0.005 0.57, 0.58 0.99
Model 6 551 0.03 0.56, 0.62 0.93
Model 1 encompasses linear regression analysis circulating CRP–aPWV;
model 2, adjusted for diabetes, body mass index (SD), systolic blood pressure
(SD), waist–hip ratio, smoking, and social class; model 3, as model 2 plus
triglycerides, cholesterol, HDL, -glutamyltransferase, liver and total alkaline
phosphatase, and alcohol consumption; model 4, as model 3 plus work and
leisure activity and presence of ischemic heart disease; model 5, linear
regression analysis CRP genotype–aPWV; model 6, as model 5, adjusting for
total cholesterol.
*aPWV adjusted for age, heart rate, mean arterial pressure, and vasoactive
medication use.
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between CRP genotype and circulating CRP levels. However,
there was no evidence of an association between CRP
genotype and aPWV. This challenges the proposition that
circulating CRP has a causal effect on aPWV and supports
the notion that observational relationships between the two
may be the result of either reverse causation or confounding.
Genotypic effects can be thought of as lifetime exposures
that cannot be altered (although there may be interactions
with other genes or environmental factors), and their random
allocation at conception can be thought of as a paralogue to
the design of a randomized controlled trial, hence providing
good evidence for causal inferences.32 Therefore, if CRP was
causally related to aPWV and, hence, arterial stiffness, then
we would have expected a difference in PWV according to
the CRP genotypes that was proportionate to the effect of the
same CRP genotypes on circulating levels of CRP.
Two previous publications investigated the relationship
between CRP genotype and PWV to date.26,27 Morita et al
based their findings on 315 elderly (mean age 77.9 years)
Japanese men and women recruited from the New Elder
Citizen Movement. They analyzed 5 SNPs in the CRP gene
and found a significant association with the C-allele of
rs1800947 compared with the G-allele (P0.04). However,
their haplotypic analysis showed a paradoxical effect because
although the H4 haplotype (TTG haplotype of rs1341665,
rs3091244, and rs1800947) was associated with a greater
proportion of subjects with elevated CRP levels (16.2%
versus 3.2%; P0.002), it was also associated with a reduced
risk of having increased PWV, defined as 14m/s (89%
versus 97%; P0.038 using Fisher’s exact test).
Schnabel et al investigated the association between multi-
ple inflammatory biomarker genotypes and arterial stiffness
measures. In their study, they analyzed 2409 participants of
the Framingham Heart Study with diverse ethnic back-
grounds and a mean age of 60 years. Their findings do not
support an association between CRP genotype (specifically
rs1800947) and aPWV.
Our study supports the evidence against a causal relation-
ship between CRP genotype and PWV. As such, this does
suggest a possible confounding effect in the relationship
between circulating CRP and PWV for which previous
studies have not adjusted. Alternatively, given that arterial
stiffness begins much earlier in life, this may in turn induce
an inflammatory response with secondary elevation of CRP
levels. A recent review33 reports several studies that linked
certain CRP polymorphisms to circulating CRP levels, and in
some, there is an association with cardiovascular outcomes.
However, one study presenting such findings34 also reported
no association between CRP polymorphisms and carotid
intima-media thickness.
Timpson et al35 found a relationship between circulating
CRP and factors of the metabolic syndrome; however, this
was abolished if CRP genotypes were analyzed instead,
which suggests CRP is a marker of the metabolic syndrome
that plays no active role in its development. Similarly, Davey
Smith et al36 report an association among CRP levels and
blood pressure, pulse pressure, and hypertension, which is not
supported by a Mendelian randomization approach examin-
ing the predicted effects of CRP genotype on these outcomes
using an instrumental variable analysis.
There are several strengths to our study. First, it is
population based and recruited men living in a well-defined
geographic population. Our measure of serum CRP is based
on 2 blood samples taken over 4 to 5 years and, hence, is less
prone to regression to the mean bias.37 CRP levels were
measured 15 years before the aPWV assessment and so
should be less influenced by reverse causality. We have also
been able to adjust for a wide range of other covariates that
may have confounded the association.
There are several important limitations to our study. First,
our cohort consisted of Welsh male participants, hence its
generalizability may be limited, although it is not obvious
why the biological effects of CRP should differ by gender or
ethnicity. In addition, our sample size cannot rule out mod-
erate size effects given the width of our 95% CI. Therefore,
larger population-based studies are still needed to confirm or
refute our findings. Finally, we were only able to examine the
survivors of the cohort, which could have introduced a
healthy survivor effect. This bias would result in an under-
estimation of the association, but despite this, we still found
a strong association between circulating CRP and aPWV,
consistent with other studies.10,13–16,18 –21 These studies
largely report an association between CRP or log–CRP and
aPWV in middle-aged or elderly healthy populations, with
widely ranging participant numbers. We do not feel that this
is a major bias because our results are identical to the report
from the Framingham Offspring Study,27 in which the mean
age of participants was10 years younger and, hence, would
have less selective mortality.
Perspectives
The findings of this study imply that CRP may have no
causal role in arterial stiffness, although future larger
Table 5. Haplotype Analysis of CRP Polymorphisms With aPWV
Haplotype
Allelic
Complement Frequency SE
Mean CRP/Ratio of Geometric
Means (95% CI) P Value
Mean aPWV/Ratio of Geometric
Means (95% CI) P Value
111 CGC 0.34 0.009 1.75 (1.55, 2.00) . . . 11.16 (10.75, 11.58) . . .
121 CAC 0.33 0.009 1.05 (0.96, 1.15) 0.3 1.00 (0.97, 1.03) 0.9
112 CGT 0.26 0.009 0.94 (0.85, 1.03) 0.2 0.99 (0.96, 1.02) 0.6
212 GGT 0.07 0.005 0.79 (0.67, 0.93) 0.004 1.01 (0.96, 1.07) 0.7
Overall P for the whole model P0.004 (log-rank test for null model compared with that including all haplotypes). Haplotype 111 (bold) is set at baseline for
regression of circulating CRP on haplotype, as performed by SIMHAP (taking into account the posterior probability of haplotype reconstruction). All other figures
represent ratios of geometric means for difference by haplotype. Common haplotypes together account for 99% of the population and account for 1% of the
variance in circulating CRP.
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studies are required to confirm our observations. This does
not exclude the value of circulating CRP as a biochemical
marker for the prediction of atherosclerotic disease or a
prognostic indicator for patients with established cardio-
vascular disease.
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